{"id":790,"date":"2015-08-14T18:21:23","date_gmt":"2015-08-14T18:21:23","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=790"},"modified":"2026-02-25T00:41:23","modified_gmt":"2026-02-25T00:41:23","slug":"clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/","title":{"rendered":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans)"},"content":{"rendered":"<p>Neurofibromatosis 2 is an inherited condition that predisposes to tumours of the nerve sheath (schwanomas) and brain lining (meningiomas). Most patients develop deafness and other handicaps that reduce life expectancy. In 1192 NF2 patients followed for an average of over 9 years, we confirmed that life expectancy was reduced when NF2 was diagnosed at a younger age, meningiomas were present, or certain particular kinds of genetic mutations caused the disease. We also showed that NF2 patients diagnosed in more recent decades had better survival than patients diagnosed earlier, reflecting improvements in diagnostic methods and treatment. (<a href=\"http:\/\/jmg.bmj.com\/content\/early\/2015\/08\/14\/jmedgenet-2015-103290\">http:\/\/jmg.bmj.com\/content\/early\/2015\/08\/14\/jmedgenet-2015-103290<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-791\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge-240x300.jpg\" alt=\"dge\" width=\"240\" height=\"300\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge-240x300.jpg 240w, https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge.jpg 428w\" sizes=\"auto, (max-width: 240px) 100vw, 240px\" \/><\/a><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neurofibromatosis 2 is an inherited condition that predisposes to tumours of the nerve sheath (schwanomas) and brain lining (meningiomas). Most patients develop deafness and other handicaps that reduce life expectancy. In 1192 NF2 patients followed for an average of over 9 years, we confirmed that life expectancy was reduced when NF2 was diagnosed at a [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-790","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Neurofibromatosis 2 is an inherited condition that predisposes to tumours of the nerve sheath (schwanomas) and brain lining (meningiomas). Most patients develop deafness and other handicaps that reduce life expectancy. In 1192 NF2 patients followed for an average of over 9 years, we confirmed that life expectancy was reduced when NF2 was diagnosed at a [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2015-08-14T18:21:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T00:41:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"428\" \/>\n\t<meta property=\"og:image:height\" content=\"534\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans)\",\"datePublished\":\"2015-08-14T18:21:23+00:00\",\"dateModified\":\"2026-02-25T00:41:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/\"},\"wordCount\":120,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2015\\\/08\\\/dge-240x300.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/\",\"name\":\"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2015\\\/08\\\/dge-240x300.jpg\",\"datePublished\":\"2015-08-14T18:21:23+00:00\",\"dateModified\":\"2026-02-25T00:41:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2015\\\/08\\\/dge.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2015\\\/08\\\/dge.jpg\",\"width\":428,\"height\":534},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2015\\\/08\\\/14\\\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/","og_locale":"en_US","og_type":"article","og_title":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans) - JMG Contact blog","og_description":"Neurofibromatosis 2 is an inherited condition that predisposes to tumours of the nerve sheath (schwanomas) and brain lining (meningiomas). Most patients develop deafness and other handicaps that reduce life expectancy. In 1192 NF2 patients followed for an average of over 9 years, we confirmed that life expectancy was reduced when NF2 was diagnosed at a [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/","og_site_name":"JMG Contact blog","article_published_time":"2015-08-14T18:21:23+00:00","article_modified_time":"2026-02-25T00:41:23+00:00","og_image":[{"width":428,"height":534,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans)","datePublished":"2015-08-14T18:21:23+00:00","dateModified":"2026-02-25T00:41:23+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/"},"wordCount":120,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge-240x300.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/","url":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/","name":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge-240x300.jpg","datePublished":"2015-08-14T18:21:23+00:00","dateModified":"2026-02-25T00:41:23+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2015\/08\/dge.jpg","width":428,"height":534},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2015\/08\/14\/clinical-and-molecular-predictors-of-mortality-in-neurofibromatosis-2-a-uk-national-analysis-of-1192-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients (Contributed by Prof D Gareth Evans)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=790"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/790\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}